Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04748185 | Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies | completed | — | 358 | Mayo ClinicOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05900765 | A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05896046 | SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03077828 | Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 43 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03226249 | PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT01141959 | Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients | completed | — | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT03860376 | Ex Vivo Drug Sensitivity Testing and Mutation Profiling | completed | — | 25 | Florida International UniversityOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05455268 | Information Support Using an Online Learning Platform for Malaysian Pediatric Leukemia and Lymphoma Parents(eHOPE) | completed | N/A | 51 | Universiti Kebangsaan Malaysia Medical CentreOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT03776864 | Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | terminated | Phase 2 | 6 | University of WashingtonOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05840575 | Investigating Cognitive Impairment in Young Patients With Cancer Prospectively(MyBrain) | recruiting | — | 100 | Rigshospitalet, DenmarkOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT02581007 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | completed | Phase 2 | 25 | Northside Hospital, Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05169151 | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT03969693 | Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation | not yet recruiting | — | 50 | Chang Gung Memorial HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05490953 | Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma | unknown | Phase 4 | 30 | University of GuadalajaraOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT00428688 | Endothelial Function and IMT in Survivors of Hodgkin's Lymphoma | completed | — | 27 | Sheba Medical CenterOTHER_GOV | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04268706 | Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) | active not recruiting | Phase 2 | 97 | Tessa TherapeuticsINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05352828 | Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy(ACTION) | active not recruiting | Phase 1 | 15 | Tessa TherapeuticsINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT01316146 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) | withdrawn | Phase 1 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT02300402 | Detection and Characterization of Residual Masses in Lymphomas(ADAMANTIUS) | completed | — | 120 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT03923504 | Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx | completed | N/A | 12 | Virginia Commonwealth UniversityOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | completed | Phase 1 | 14 | Brenda Cooper, MDOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 46 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02593123 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | completed | Phase 2 | 31 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT04629430 | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT(HCTDiet) | completed | N/A | 40 | University of VirginiaOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT05188755 | Fitness Assessment in Young Adults Recovered From Lymphoma(CUPCAKE) | completed | N/A | 44 | University Hospital, Clermont-FerrandOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05663983 | Multicentric and Retrospective Analysis of Adolescent Young Adult (AYA) Hodgkins' Lymphoma Patients | unknown | — | 600 | Campus Bio-Medico UniversityOTHER | 0 | Dec 23, 2022 | clinicaltrials |
| NCT05660993 | Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma | unknown | Phase 2 | 50 | National Research Center for Hematology, RussiaNETWORK | 1 | Dec 21, 2022 | clinicaltrials |
| NCT00739141 | Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. | completed | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT01272817 | Nonmyeloablative Allogeneic Transplant(Mini-allo) | completed | N/A | 36 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT01364363 | Unrelated Donor Stem Cell Transplantation | completed | N/A | 64 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05254821 | Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients | unknown | — | 130 | Federico II UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT02572167 | A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 93 | Seagen Inc.INDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03505996 | A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 2 | 82 | CStone PharmaceuticalsINDUSTRY | 1 | Oct 31, 2022 | clinicaltrials |
| NCT02098512 | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | unknown | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT00145600 | Therapy for Pediatric Hodgkin Lymphoma | completed | Phase 2 | 296 | St. Jude Children's Research HospitalOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01030900 | Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03552003 | Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis | unknown | — | 400 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05518318 | GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL) | unknown | Phase 3 | 60 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 0 | Aug 26, 2022 | clinicaltrials |
| NCT02292979 | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.(BREACH) | completed | Phase 2 | 170 | The Lymphoma Academic Research OrganisationOTHER | 5 | Aug 19, 2022 | clinicaltrials |
| NCT03580408 | Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma | completed | Phase 2 | 64 | The Lymphoma Academic Research OrganisationOTHER | 2 | Aug 19, 2022 | clinicaltrials |
| NCT03480087 | Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma(Cardiocare) | completed | — | 118 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT02404818 | Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy | completed | — | 5 | University of FloridaOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT05410314 | Nutritional Supplement Based on Myo-inositol-D-chiro-inositoln in Long-term Survivors of Lymphoma(Linf-inositol) | completed | — | 90 | University of Bari Aldo MoroOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT03302728 | Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma(EpiBrentlen) | completed | Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jul 10, 2023source: clinicaltrials